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Abstract
Acetyl coenzyme A carboxylase B gene (ACACB) single nucleotide polymorphism (SNP) rs2268388 is reproducibly associated
with type 2 diabetes (T2DM)-associated nephropathy (DN). ACACB knock-out mice are also protected from obesity. This
study assessed relationships between rs2268388, body mass index (BMI) and gene expression in multiple populations, with
and without T2DM. Among subjects without T2DM, rs2268388 DN risk allele (T) associated with higher BMI in Pima Indian
children (n = 2021; p-additive = 0.029) and African Americans (AAs) (n = 177; p-additive = 0.05), with a trend in European
Americans (EAs) (n = 512; p-additive = 0.09), but not Germans (n = 858; p-additive = 0.765). Association with BMI was seen in
a meta-analysis including all non-T2DM subjects (n = 3568; p-additive = 0.02). Among subjects with T2DM, rs2268388 was
not associated with BMI in Japanese (n = 2912) or EAs (n = 1149); however, the T allele associated with higher BMI in the
subset with BMI$30 kg/m2 (n = 568 EAs; p-additive = 0.049, n = 196 Japanese; p-additive = 0.049). Association with BMI was
strengthened in a T2DM meta-analysis that included an additional 756 AAs (p-additive = 0.080) and 48 Hong Kong Chinese
(p-additive = 0.81) with BMI$30 kg/m2 (n = 1575; p-additive = 0.0033). The effect of rs2268388 on gene expression revealed
that the T risk allele associated with higher ACACB messenger levels in adipose tissue (41 EAs and 20 AAs with BMI.30 kg/
m2; p-additive = 0.018) and ACACB protein levels in the liver tissue (mixed model p-additive = 0.03, in 25 EA bariatric surgery
patients with BMI.30 kg/m2 for 75 exams). The T allele also associated with higher hepatic triglyceride levels. These data
support a role for ACACB in obesity and potential roles for altered lipid metabolism in susceptibility to DN.
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Introduction
There is a world-wide epidemic of type 2 diabetes mellitus
(T2DM) and chronic diabetes complications are major public
health concerns [1]. Dyslipidemia associates with risk for T2DM
and its complications, particularly diabetic nephropathy (DN) [2].
ACACB is the rate-limiting enzyme for fatty acid oxidation, and
single nucleotide polymorphism (SNP) rs2268388 in the acetyl
coenzyme A carboxylase B gene (ACACB) is reproducibly
associated with T2DN and diabetic end-stage renal disease
(ESRD) [3,4]. Relative to the C allele, a 29-bp DNA fragment
containing the T risk allele of rs2268388 demonstrated greater
enhancer activity in cultured human renal proximal tubular
epithelial cells, indicating higher ACACB expression in risk allele
carriers [3]. Genome-wide association studies (GWAS) and the
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HapMap database have not revealed other SNPs in high genotypic
concordance with rs2268388. In addition, the T allele of
rs2268388 is overrepresented in obese women with T2DM and
had higher transcription binding affinity than the C allele [5].
Therefore, rs2268388 could contribute to regulation of metabo-
lism, alterations in lipids, and adiposity. We prioritized this SNP in
order to explore potential links between predisposition to DN and
lipid dysregulation in subjects with T2DM.
We previously examined association of rs2268388 and ten other
common coding ACACB variants with metabolic traits and gene
expression [6]. Although significant associations were detected
with gene expression and several metabolic traits for coding
variants, we failed to associate rs2268388 with expression
quantitative trait loci (QTL) or metabolic traits. This may have
been due to low allele frequencies with reduced power or
undetected gene*environment interactions [6].
To assess the role of the DN-associated ACACB SNP rs2268388
on body mass index (BMI), we tested for association between this
SNP and BMI in four population groups, including Europeans
and European Americans (EAs), African Americans (AAs), Pima
Indians and Asians. Subjects with and without T2DM were
assessed, with a focus on those with high BMI. Effects on gene
expression were investigated in multiple tissues and cell types.
Materials and Methods
Study samples
Table 1 contains demographic data in study participants. All
participants provided written informed consent.
Wake Forest School of Medicine (WFSM) Diabetes Heart
Study (DHS) and African American-Diabetes Heart Study
(AA-DHS)
Subjects with T2DM in the DHS (n = 1149 EAs), AA-DHS and
AA T2D-ESRD studies (n = 1446 AAs) were born in North
Carolina, South Carolina, Georgia, Tennessee, or Virginia. Those
with a history of ketoacidosis or developing DM before the age of
25 years and receiving continuous insulin treatment since
diagnosis were excluded. For patients with ESRD, maximal pre-
dialysis BMI values were utilized. Study procedures were approved
by the WFSM Institutional Review Board (IRB) [7,8].
University of Utah (UT) and University of Arkansas (AR)
samples
EAs (n = 512) and AAs (n = 177) without T2DM ascertained in
UT and AR were evaluated under separate IRB-approved
protocols at the University of Utah Health Sciences Center and
University of Arkansas for Medical Sciences (UMAS) [9].
Participants had normal 75 g oral glucose tolerance tests
(OGTTs). A subset of the AR sample underwent adipose biopsy
(below).
Pima Indian population-based samples
A population-based sample of full-heritage Pima Indians
(n = 3,197) derived from the longitudinal study of the etiology of
T2DM in the Gila River Indian Community in Central Arizona
was evaluated [10]. This study was approved by the National
Institute of Diabetes and Digestive and Kidney Diseases IRB and
included related individuals with biennial exams measuring height,
weight, and a 75-g OGTT (WHO 1999 criteria). In the sample of
full-heritage Pima Indians, BMI was included for exams after the
age of 5 years (19,385 BMI measures in 3,197 subjects). In a subset
of the full sample, Pima children aged 5–19 years had their
maximum BMI recorded at a time when they were not yet
diagnosed with T2DM (n = 2,021).
German samples
Non-diabetic Europeans (n = 858) recruited at University
Hospital in Leipzig, Germany were included in a study approved
by the ethics committee. Diabetes was defined using WHO 1999
criteria.
Japanese samples
Samples from outpatient diabetes clinics at Shiga University of
Medical Science, Tokyo Women’s Medical University, Kawai
Clinic, and Tokai University Hospital were evaluated under IRB
approved protocols [3]. Diabetes was defined using WHO 1999
criteria, and type 2 diabetes patients with normoalbuminuria or
with microalbuminuria were included in the present analysis.
Hong Kong samples
Chinese subjects born in Hong Kong or southern China were
evaluated [4]. T2DM was diagnosed in those treated with oral
hypoglycemic agents and/or insulin, in the absence of insulin-only
treatment after one year of T2DM. The study was approved by
the IRBs at University of Hong Kong/Hospital Authority Hong
Kong West, Kowloon Central and East Clusters of Hospitals and
met criteria in the Declaration of Helsinki.
Genotyping
SNP rs2268388 was genotyped in WFSM and Hong Kong
samples using the MassARRAY genotyping system (Sequenom
Inc., San Diego, CA). PCR primers were designed using the
MassARRAY Assay Design 3.4 Software (Sequenom Inc., San
Diego, CA). The minimum SNP call rate for an individual was
98.4%. Forty-six blind duplicates were genotyped with a
concordance rate of 99.6%. The SNP was genotyped in UT,
AR, Pima Indian and German samples using the TaqMan
genotyping reaction. DNA was amplified on a GeneAmp PCR
system 9700 (95uC for 10 min, followed by 40 cycles of 95uC for
30 s and 60uC for 1 min 30 s), and fluorescence was detected on
an ABI Prism 7700 or 7500 (Applied BioSystems). Sequence
information for oligonucleotide primers and probes is available
upon request. The overall genotyping call rate exceeded 98%.
Duplicate quality control (QC) samples were randomly distributed
in the UT/AR (n = 69) and Pima (n = 150) plates assuring ,99%
reproducibility. To assess genotyping reproducibility in the
German cohort, a random ,5% selection of the sample was re-
genotyped and the genotypic concordance reached 100%. In the
Japanese cohort, the SNP was genotyped using a multiplex-PCR-
invader assay. The call rate for the SNP was 99.1% and a
concordance rate in duplicate samples (n = 1,289) was 99.6% [3].
Adipose Biopsy
149 AR non-diabetic subjects underwent a fasting adipose
biopsy under local lidocaine anesthesia [11]. Tissue was obtained
using a Bergstrom needle from abdominal sub-cutaneous fat.
Samples were rinsed in sterile saline, quick frozen in liquid
nitrogen and stored at 280uC.
Liver Biopsy
Twenty-five EAs undergoing laparoscopic gastric banding or
Roux-en-Y gastric bypass surgery at WFSM agreed to an intra-
operative wedge liver biopsy in an IRB-approved study. Patients
with liver disease other than non-alcoholic fatty liver disease
(macrosteatosis in the setting of hepatic ballooning, inflammation
ACACB and BMI
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or fibrosis), malignancy, coagulopathy or need for anticoagulation,
chronic inflammatory diseases, or ethanol intake $105 g/week (or
$45 g/day) were excluded. Hepatic lipid analysis methods in
these wedge biopsies immediately snap frozen and stored at
280uC have been reported [12]. Briefly, lipids from 50–100 mg of
minced tissue were extracted in 2:1 chloroform:methanol over-
night and triglycerides (TGs) quantified using enzymatic assays
after addition of Triton-X100 (TG and cholesterol - Roche
Diagnostics; unesterified cholesterol - Wako Chemicals USA)
[13,14]. TG content was calculated as mg (TG)/g liver total cell
lysate protein.
RNA isolation and gene transcription arrays
Total RNA was isolated from adipose using the RNAeasy Lipid
Tissue Mini kit (Qiagen, Valencia, CA). The quantity and quality
of the isolated RNA were determined by ultraviolet spectropho-
tometry and electrophoresis using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). Genome-wide tran-
scriptome analysis was performed on the AR adipose biopsy
sample using Human HT-12 v4 Expression BeadChip (Illumina,
San Diego,CA) whole-genome gene expression array according to
the vendor-recommended protocol.
Western Blot
Liver samples were homogenized in 56 volume of phosphate-
buffered saline relative to tissue weight and protease inhibitors
added. Sodium dodecyl sulfate buffer (1% sodium dodecyl sulfate,
10 mmol/L Tris, pH 7.6) was added in the amount of the
homogenate and sonicated. Equal amounts of protein for each
sample were separated by 4% to 20% sodium dodecyl sulfate-
polyacrylamide (SDS) gel electrophoresis, transferred onto a
nitrocellulose membrane (Bio-Rad, Hercules, CA) and blocked
for 1 hour at room temperature with Tris-buffered saline
containing 1% skim milk powder, 0.1% Tween 20. Blots were
incubated overnight at 4uC with a polyclonal anti-ACACB
antibody (1:1,000, Sigma, HPA006554). Membranes were washed
3 times in Tris-buffered saline containing 0.1% Tween 20 and
incubated for 1 hour in the blocking buffer with anti-rabbit IgG
conjugated to horseradish peroxidase (1:20,000; Jackson Immuno-
Research, West Grove, PA, USA). The bound antibodies were
visualized using enhanced chemiluminescence (Super Signal West
Pico; Thermo Pierce, Rockford, IL, USA) and recorded on X-ray
film. The bands were scanned and densities quantitated using
Image J (http://rsbweb.nih.gov/ij/). Liver lysate samples were
randomized before being loaded on the SDS gels for three batches
of replicated experiments.
Table 1. Demographic data of the study cohorts.
Cohort Status N(M/F) BMI(kg/m2) Age(yrs)
Leipzig German Non-diabetic 858(272/586) 28.7065.70 49.0613.5
Arkansas EAs Non-diabetic 404(129/275) 30.3065.92 38.96610.36
Utah EAs Non-diabetic 108(42/66) 27.5165.63 40.13611.32
Arkansas AAs Non-diabetic 177(71/106) 30.6866.07 39.3869.44
Pima Indians Non-diabetic children 2021(891/1130) 27.0166.31* 13.8563.98**
Arkansas adipose biopsy sample Non-diabetic (All EAs) 105(43/62) 27.7865.59 40.13610.91
Non-diabetic (All AAs) 44(27/17) 30.2066.38 43.3269.14
Non-diabetic (EAs BMI.30 kg/m2) 41(14/27) 34.5063.79 42.3069.60
Non-diabetic (AAs BMI.30 kg/m2) 20(9/11) 35.8264.37 43.7069.39
Wake Forest liver biopsy sample
EAs
26(20/6) 43.14611.61 50.0869.91
Wake Forest liver biopsy sample
AAs
3(1/2) 43.3668.82 45.00610.54
Wake Forest EAs Diabetic (All) 1149(555/594) 31.0267.13 64.2169.82
Diabetic (BMI.30 kg/m2) 568(236/332) 36.5765.60 61.6568.76
Wake Forest AAs Diabetic (All) 1446(593/853) 32.43614.29 59.41610.41
Diabetic (BMI.30 kg/m2) 756(259/497) 38.56617.10 57.2769.85
Japanese Diabetic (All) 2912(1697/1215) 24.063.8 63.2610.7
Diabetic (BMI.30 kg/m2) 196(82/114) 32.863.3 55.3613.1
HK Chinese Diabetic (All) 596(317/279) 24.5664.20 66.82610.90
Diabetic (BMI.30 kg/m2) 48(29/19) 33.8364.53 60.32612.20
Pima Indians Non-diabetic Pima children eventually
developed DM
642(259/383) max adult BMI 40.6468.79***
BMI at first DM visit 38.8868.41
age at max adult BMI
33.6769.97
age at first DM visit 32.7869.45
Pima Indians All 3197(1353/1844) max BMI 37.0268.75 age at max BMI 35.06614.21
EA: European American; AA: African American.
*The analysis used age & sex standardized z scores (mean: 0.28861.04). Mean shown is mean of max z-scores converted to BMI units using mean & SD of 12 year-old
females.
**Age shown is age at max BMI z-score; not necessarily same as age at max BMI.
***max BMI from age .15 yrs. N = 637 since 5 kids had no exams after age 15.
doi:10.1371/journal.pone.0056193.t001
ACACB and BMI
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Statistical Analyses
Statistical analyses were performed using SAS 9.1 software (SAS
Institute; Cary, NC). A generalized linear model (GENMOD) was
used to assess associations between genotype and BMI, ACACB
gene expression in adipose and ACACB protein level in liver. For
additive model analyses, homozygotes for allele (1/1), heterozy-
gotes (1/2), and homozygotes for allele (2/2) were coded to a
continuous variable (0, 1, and 2). Generalized estimating equations
(GEE) were used to account for sibships in the UT EAs, Wake
Forest, and Pima subjects, in addition to adjustment for age, sex,
and BMI. The SNP was analyzed using the same genetic model in
all analyses, regardless of the study sample. A meta-analysis was
performed using the Stouffer method [15]. Mixed model analyses
were applied for multiple exams of continuous variables (BMI for
Pima Indians and ACACB protein levels by Western blot) to
account for repeat values. P-values,0.05 were considered to
represent nominal levels of statistical significance.
Results
Association with BMI in subjects without diabetes
Figure 1 summarizes association results for BMI with
rs2268388 in non-diabetic Germans (European), UT EAs, AR
EAs, AR AAs and Pima Indians. Significant association was seen
in Pima Indian children (p = 0.0294); while the three European-
derived populations revealed non-statistically significant trends
consistent in direction. Association in non-diabetic AR AAs was
nominally significant but opposite in direction. A meta-analysis
revealed significant association (p = 0.02 Stouffer method) com-
bining all populations, mainly driven by Pima Indian children
(Figure 1).
Association with BMI in subjects with diabetes and
BMI.30 kg/m2
No significant association of BMI with rs2268388 was detected
in diabetic subjects within each cohort or the combined sample
(data not shown). However, stratified analyses revealed rs2268388
associated with BMI in subjects with T2DM and BMI$30 kg/m2
in Japanese (p = 0.049) and WFSM EAs (p = 0.049), with a non-
significant trend in WFSM diabetic AAs (p = 0.08). No association
was seen in Hong Kong Chinese (p = 0.81), but the direction was
consistent. A meta-analysis in combined WFSM AAs, WF EAs,
Japanese and Hong Kong Chinese with T2DM and BMI$30 kg/
m2 revealed significant evidence of association (p = 0.0033;
Figure 2).
Association with BMI in Pima Indians
BMI z-scores were evaluated in all full-heritage Pima subjects
,18 years of age who had at least one non-diabetic exam and who
then subsequently developed T2DM (Model 1, n of subjects = 642,
N of exams = 5321). In addition, all BMI exams in all recorded
full-heritage Pima Indians genotyped for rs2268388 were evalu-
ated in Model 2 (n of subjects = 3197, N of exams = 19385). BMI
was not associated with rs2268388 in Model 1 (mixed model
analysis p = 0.265, Table 2). However, when all BMI exam z-
scores were examined in Model 2, a trend toward association was
seen (mixed model analysis p = 0.0755; Table 2). Subjects in
model 1 had diabetes, with BMIs recorded longitudinally after
their initial non-diabetic exams. Pima Indians have a high
prevalence of T2D; a majority will ultimately develop T2DM.
Therefore, we included both models with the full WF AA, WF EA,
Japanese and Hong Kong Chinese T2DM study samples. A meta-
analysis for BMI and rs2268388 in all subjects with T2DM
revealed significant association (Stouffer method p = 0.0022 with
Model 1 and p = 0.01 with Model 2, respectively; Table 2).
Association with ACACB messenger level in non-diabetic
subjects
The messenger level of ACACB was measured by Human HT-
12 v4 BeadChip (Illumina, San Diego,CA) whole-genome gene
expression array in AR non-diabetic EAs and AAs with
subcutaneous adipose tissue (all had an OGTT). Significant
association was not observed in the full biopsy sample (n = 149,
data not shown). A nominally significant association between
ACACB messenger level and rs2268388 was seen in subjects with
BMI$30 kg/m2 (p = 0.018) adjusting for age, gender, BMI, and
ethnicity (Figure 3), where the (T) risk allele for higher ACACB
messenger level was consistent with associations with higher BMI.
Association with liver ACACB protein level
Figure 4 reveals significant association between liver ACACB
protein level and rs2268388 in EAs who underwent bariatric
surgery (BMI.30 kg/m2, n = 25 with 75 total Western blot
exams; p = 0.03). The (T) risk allele for higher ACACB protein
level was consistent with associations with higher BMI.
Association with hepatic triglycerides (TGs)
Figure 5 reveals that rs2268388 was associated with higher
hepatic intracellular TGs in 26 EA and 3 AA subjects who
underwent bariatric surgery (BMI.30 kg/m2; p = 0.03). The (T)
risk allele for higher TG was consistent with associations with
higher BMI.
Discussion
ACACB is a rate-limiting enzyme involved in mitochondrial
fatty acid oxidation and plays a key role in fatty acid metabolism
[16–19]. The current results reveal that ACACB SNP rs2268388
(reproducibly implicated in risk of nephropathy) associates with
BMI in general populations and with obesity in subjects with T2D,
as well as impacts gene expression in adipose and hepatic tissue.
ACACB cis SNPs reportedly regulate ACACB gene expression,
providing potential roles for effects on adiposity [6]. Adipose
ACACB expression was negatively associated with adiposity
(p = 0.0002, r =20.35) in EAs [6] and Pima Indians
(p = 4.3610212, r =20.45, personal communication [20]). Feed-
back regulation has been observed by significant down-regulation
of ACACB mRNA with free fatty-acid (palmitate or oleate)
treatment [21], as well as reductions in ACACB protein expression
(data not shown). This implicates a complex cross-regulation
between ACACB gene expression and adiposity.
Although ACACB is a physiological candidate gene for obesity
and diabetes, significant association has not been observed in
GWAS. This may reflect the effect of gene*gene or gene*environ-
ment interactions. A recent gene*environment interaction study of
ACACB variants in metabolism suggests that undiscovered
causative variants may have been overlooked [22]. Associations
between ACACB and obesity in general populations can be masked
by environmental factors such as lifestyle and eating behaviors
linked with development of adiposity. Acacb knock-out mice are less
likely to gain weight when fed high-fat diets compared to their wild
type littermates; however, significant differences in body weight
were not observed when fed normal chow [16]. This phenomenon
has been observed in other rodent models where overweight
phenotypes are conditional on diet [23,24].
ACACB variant rs2268388 is reproducibly associated with DN
[3,4]. There is also evidence implicating altered lipid metabolism
ACACB and BMI
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in the pathogenesis of DN [25,26]. PPARA agonists (fibrates), up-
regulating fatty acid oxidation, may improve DN in humans
[27,28] and animal models [29]. Accelerated DN was observed in
mice lacking the peroxisome proliferator-activated receptor alpha
[30]. The mechanism of ACACB association with DN remains
unknown.
ACACB variant rs2268388 was also associated with severe
obesity in Spanish women, no data were provided in men [5]. We
chose to perform the association analyses for this SNP with BMI in
multiple samples, including general populations of non-diabetic
subjects, subjects with T2DM, and subjects with T2DM and
BMI$30 kg/m2. We selected non-diabetic Pima childhood max
BMI z-score to represent non-diabetic BMI measures for Pimas,
Figure 1. Association of rs2268388 with BMI in non-diabetic subjects.
doi:10.1371/journal.pone.0056193.g001
ACACB and BMI
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since adult BMIs are usually high and largely impacted by
environmental factors, and are very close to the first visit diabetic
BMIs. However, it is informative to know that significant
association was not observed between rs2268388 and maximum
BMI in adult Pima Indians when non-diabetic (detailed data not
shown). Our finding of association with BMI in obese African
American subjects with T2D was consistent with the report in
Spanish women [5]. Women, not men, contributed to the
significant association in AAs (Figure S1-1); whereas gender
interaction was not observed in EAs (Figure S1-2). In full-
heritage Pima subjects ,18 years of age who had at least one non-
diabetic exam and who then subsequently developed T2DM
(Model 1), there was a weak trend that men, not women, with T
allele were heavier, and genotype*gender interaction was border-
line significant; however no significant gender interaction was
observed in all full-heritage Pimas for all recorded BMI exams
(Model 2) (Table S1). Due to limited sample power for obese
diabetic subjects of the Japanese and Chinese cohorts, additional
gene*gender interaction analysis was not attempted for those two
ethnic groups. Severe obesity in the Spanish population was
defined as BMI$35 kg/m2, whereas we chose BMI$30 kg/m2 to
capture obese Japanese and Hong Kong Chinese subjects.
Although association with high BMI in any single population
was relatively weak, overall effects in combined samples appeared
stronger. BMI data in Pima Indians from an on-going half-century
long longitudinal study were included. Full-heritage Pima Indians
have minimum admixture from other populations and many had
BMI records starting in childhood. This allowed us to perform
mixed model analyses testing association of rs2268388 with BMI
z-scores from multiple exams in every individual, rather than a
single exam in each subject. This was important since BMI
changes during life. The majority of Pima subjects’ BMI exceed
34 kg/m2 in adulthood for the younger generations (Figure S2)
and 80% of those aged above 55 years have T2DM [31].
ACACB gene expression by genotype revealed the same pattern
with BMI in our combined Arkansas EA and AA samples, the
Figure 2. Association of rs2268388 with BMI in subjects with type 2 diabetes and BMI$30 kg/m2.
doi:10.1371/journal.pone.0056193.g002
ACACB and BMI
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rs2268388 DN ‘‘T’’ risk allele represented higher expression levels
with BMI$30 kg/m2. Higher ACACB expression is linked to
obesity and insulin resistance in a mouse model fed a high-fat diet
[17]. ACACB RNA expression levels were also elevated in
transformed lymphoblast cell lines from subjects with the T allele
in a combined analysis of CEU (Utah European ancestry
population), Japanese and Yoruba samples (HapMap-Sanger gene
expression database, Figure S3) (http://www.hapmap.org &
ftp://ftp.sanger.ac.uk/pub/ genevar/). Two groups reported that
Acacb knock-out mice had similar body weights as wild type mice
[32,33]. Molecular explanations for the phenotypic differences
observed between Olson’s model [32] of Acacb deletion and that of
Abu-Elheiga et al [16] resistant to obesity, diabetes and insulin
resistance are unclear. The Acacb biotin-binding site was deleted in
both models, but using different approaches. The targeting
strategy employed in the original study replaced only the exon
containing the biotin binding motif [16]. RNA splicing across the
targeting cassette could have left the mRNA in frame, resulting in
a mutated but otherwise intact protein lacking a catalytic domain.
Such a protein could have ‘‘dominant negative’’ activity toward
ACACA [33] where both ACACB and ACACA activities are
inhibited. This is consistent with the effects of soraphen, an
inhibitor of both ACACA and ACACB which improved
peripheral insulin sensitivity in mice fed a high-fat diet [34].
Our report benefits from a liver tissue repository allowing
performance of a Western blot analysis assessing ACACB protein
levels in hepatic cell lysates from obese subjects undergoing
bariatric surgery (Figure S4). Subjects with the T risk allele
tended to have higher ACACB protein levels in liver cells,
consistent with association of this SNP with ACACB RNA levels in
adipose tissue from non-diabetic EA and AA subjects with
BMI$30 kg/m2. In addition, bariatric surgery subjects with the
Table 2. Association of rs2268388(C/T) with BMI in full-heritage Pima Indian longitudinal cohort.
Analysis CC CT TT Beta P-value
BMI z-score6SE BMI z-score 6SE BMI z-score 6SE
(n_CC/N_exams) (n_CT/N_exams) (n_TT/N_exams)
model 1 0.25360.038 0.37360.058 0.04760.206 0.065 0.26531
(470/3987) (162/1257) (10/77)
Meta-analysis together with 4 cohorts (Japanese, HK Chinese, Wake Forest EAs and AAs) in Figure 2 (Stouffer method) 0.0022
model 2 20.00260.020 0.06360.031 0.03960.097 0.052 0.07551
(2367/14422) (765/4565) (65/398)
Meta-analysis together with 4 cohorts (Japanese, HK Chinese, Wake Forest EAs and AAS) in Figure 2 (Stouffer method) 0.01
model 1: .= 1 nondiabetic exam age ,18 and subsequently developed DM; total n = 642; total exam N=5321;
P values were adjusted for age, gender, sibship, and repeated exams (matrix: autoregressive; additive genetic model).
model 2: All individuals- all examinations; total n = 3197; total exam N=19385;
P values were adjusted for age, gender, sibship, diabetic status, duration of diabetes, and repeated exams (matrix: autoregressive; additive genetic model).
T allele is defined as risk allele for higher BMI z-score.
n_CC, n_CT, n_TT: number of individuals in each genotypic group. N_exams: number of exams.
doi:10.1371/journal.pone.0056193.t002
Figure 3. Adipose ACACB expression by rs2268388.
doi:10.1371/journal.pone.0056193.g003
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T allele tended to have higher liver TG levels. Abu-Elheiga et al.
reported that Acacb knock-out mice were also protected against
fatty liver during high-fat, high-carbohydrate diet and de novo
lipogenic conditions [35]. These data support that metabolic
changes with mutant ACACB may be conditional on nutritional
status. The ACACB pathway may be a useful target for
ameliorating metabolic syndrome.
Limitations of this study were small numbers of Asian samples
and all except the Pima lacked longitudinal BMI data. The sample
numbers in our gene expression studies had limited statistical
power. However, we estimate the liver cohort had approximately
0.80 genetic power for detecting 20% of the variation in protein
expression levels (assuming type 1 error rate = 0.005) using mixed
models for triplicate Western blot analyses under unstructured
matrix and adjustment to account for across experiment variance.
Figure 4. Liver ACACB expression by rs2268388.
doi:10.1371/journal.pone.0056193.g004
Figure 5. Liver cell triglyceride (TG) by rs2268388.
doi:10.1371/journal.pone.0056193.g005
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We conclude that the T allele for ACACB SNP rs2268388
associates with higher BMI in subjects with diabetes and
BMI$30 kg/m2 and in general non-diabetic populations. The T
allele also associates with higher ACACB expression in subjects with
elevated BMI at the RNA (adipose) and protein levels (liver).
Intracellular hepatic TGs are also elevated with this allele. GWAS
for BMI, obesity and T2DM may not identify metabolism-related
genes involved in these processes when nutritional status and
lifestyles are assumed to be homogenous. ACACB variants may
regulate gene expression and impact BMI; however, adiposity can
also impact ACACB gene expression and balance the effects of
genetic variation [5]. The ACACB rs2268388 association with DN
has been replicated in multiple populations and the T risk allele for
DN appears consistent with that of higher BMI, elevated liver TGs
and metabolic cell gene expression. Alterations in lipid metabolism
may jointly impact development of DN and obesity.
Supporting Information
Figure S1 BMI vs. rs2268388 in Wake Forest diabetic men and
women. S1-1. BMI vs. rs2268388 in Wake Forest diabetic African
Americans (AAs) (a: men BMI.30 kg/m2; b: women
BMI.30 kg/m2; c: men; d: women). S1-2. BMI vs. rs2268388
in Wake Forest diabetic European Americans (EAs) (BMI.30 kg/
m2) (a: men; b: women).
(JPG)
Figure S2 BMI distribution by age for different birth era groups
in non-diabetic full-heritage Pima Indians.
(JPG)
Figure S3 ACACB expression in transformed lymphoblast cell
lines in HapMap/Sanger gene expression data set (in CEU, JPT,
&YRI).
(JPG)
Figure S4 Liver ACACB protein level (an example gel image for
Western Blot) in Caucasians (underwent bariatric surgery:
BMI.30 kg/m2).
(JPG)
Table S1 Association of rs2268388(C/T) with BMI in full-
heritage Pima Indian men and women.
(PDF)
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